



CCM DUOPHARMA BIOTECH BERHAD (524271-W)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 JUNE 2018**

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR	PRECEDING YEAR	CURRENT YEAR	PRECEDING YEAR
	QUARTER	CORRESPONDING QUARTER	TO DATE	CORRESPONDING PERIOD
	6/30/2018 RM'000	6/30/2017 RM'000	6/30/2018 RM'000	6/30/2017 RM'000
Revenue	123,991	117,049	257,250	240,355
Cost of Sales	(71,717)	(67,394)	(152,335)	(146,098)
Gross Profit	52,274	49,655	104,915	94,257
Other operating income	103	35	170	136
Distribution costs	(17,778)	(22,187)	(37,673)	(39,952)
Administration expenses	(19,247)	(13,640)	(37,493)	(27,291)
Other operating expenses	(1,080)	(470)	(1,379)	(1,037)
Profit from operations	14,272	13,393	28,540	26,113
Finance income	257	588	702	1,303
Finance costs	(1,614)	(1,339)	(3,072)	(2,652)
Profit before taxation	12,915	12,642	26,170	24,764
Taxation	(2,576)	(3,001)	(5,184)	(5,559)
Profit after tax for the period	10,339	9,641	20,986	19,205
Other comprehensive income				
Fair value of available-for-sale financial assets	(14,844)	-	(14,844)	-
Foreign currency translation differences for foreign operations	133	12	268	12
Total other comprehensive income/ (loss) for the period	(4,372)	9,653	6,410	19,217
Profit attributable to:				
Shareholders of the Company	10,339	9,653	20,986	19,217
Minority interest	-	-	-	-
	10,339	9,653	20,986	19,217
Total comprehensive income/ (loss) attributable to:				
Shareholders of the Company	(4,372)	9,653	6,410	19,217
Minority interest	-	-	-	-
	(4,372)	9,653	6,410	19,217
Earnings per share (sen)				
Basic (based on weighted average)	3.69	3.46	7.50	6.88
Diluted (based on weighted average)	3.69	3.46	7.50	6.88

- The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2017 and the accompanying explanatory notes attached to the interim financial statements.